Contineum Therapeutics, Inc. Shares Authorized
Contineum Therapeutics, Inc. (CTNM) had Shares Authorized of 220.00 million shares as of 2024-04-09, per its 10-K filed 2026-03-05.
Financial Statements › Balance Sheet › Equity › Stockholders' Equity, Number of Shares, Par Value and Other Disclosure
us-gaap:CommonStockSharesAuthorized · last filed 2026-03-05
- 2024-04-09: Common Stock, Shares Authorized 220.00M shares.
- 2024-03-31: Common Stock, Shares Authorized 39.63M shares.
- 2023-12-31: Common Stock, Shares Authorized 39.63M shares.
- 2023-04-10: Common Stock, Shares Authorized 39.63M shares.
| Period end | Common Stock, Shares Authorized |
|---|---|
| 2024-04-09 | 220.00M shares 10-K · filed 2026-03-05 |
| 2024-03-31 | 39.63M shares 10-Q · filed 2024-05-16 |
| 2023-12-31 | 39.63M shares 10-Q · filed 2024-05-16 |
| 2023-04-10 | 39.63M shares 10-Q · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |